- Home
- TLSA vs IAF Comparison
TLSA vs IAF Comparison
Compare TLSA & IAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TLSA | IAF |
|---|---|---|
| Founded | 2013 | 1985 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.1M | 118.7M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | TLSA | IAF |
|---|---|---|
| Price | $1.18 | $12.69 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.02 | N/A |
| AVG Volume (30 Days) | ★ 582.2K | 20.9K |
| Earning Date | 05-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.44% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.76 | $4.36 |
| 52 Week High | $2.20 | $14.54 |
Technical Indicators
Market Signals| Indicator | TLSA | IAF |
|---|---|---|
| Relative Strength Index (RSI) | 60.42 | 40.07 |
| Support Level | $1.14 | $12.31 |
| Resistance Level | $1.20 | $12.96 |
| Average True Range (ATR) | 0.09 | 0.17 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 76.81 | 32.71 |
Price Performance
Historical ComparisonAbout TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.
About IAF abrdn Australia Equity Fund Inc.
Abrdn Australia Equity Fund Inc is a non-diversified closed-end management investment company. The Fund's principal investment objective is long-term capital appreciation through investment in equity securities of Australian companies listed on the Australian Stock Exchange Limited (ASX). Its secondary objective is current income, which is expected to be derived from dividends and interest on Australian corporate and governmental securities.